PRS-02: Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy …
JY Douillard, E Kim, V Hirsh, T Mok, M Socinski… - Journal of thoracic …, 2007 - jto.org
Background: This Phase III, randomized, open-label, multicenter, parallel-group study
(INTEREST [IRESSA non-small-cell lung cancer (NSCLC) Trial Evaluating REsponse and …
(INTEREST [IRESSA non-small-cell lung cancer (NSCLC) Trial Evaluating REsponse and …
Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients …
G Scagliotti, J Von Pawel, S Novello… - Journal of Clinical …, 2015 - ascopubs.org
Purpose Tivantinib, a MET receptor tyrosine kinase inhibitor, demonstrated increased
anticancer activity in preclinical and early clinical studies when combined with erlotinib. Our …
anticancer activity in preclinical and early clinical studies when combined with erlotinib. Our …
Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience …
XL Mu, LY Li, XT Zhang, SL Wang, MZ Wang - BMC cancer, 2004 - Springer
Background The gefitinib compassionate-use programme has enabled> 39,000 patients
worldwide to receive gefitinib ('Iressa', ZD1839) treatment. This paper reports the outcome of …
worldwide to receive gefitinib ('Iressa', ZD1839) treatment. This paper reports the outcome of …
Erlotinib for frontline treatment of advanced non–small cell lung cancer: a phase II study
G Giaccone, M Gallegos Ruiz, T Le Chevalier… - Clinical Cancer …, 2006 - AACR
Purpose: Erlotinib has proven activity in pretreated patients with advanced non–small cell
lung cancer (NSCLC). We evaluated erlotinib in the frontline treatment of advanced NSCLC …
lung cancer (NSCLC). We evaluated erlotinib in the frontline treatment of advanced NSCLC …
Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized …
T Moran, E Felip, V Keedy, H Borghaei… - … hematology & oncology, 2014 - Springer
Background We investigated the safety and antitumor activity of dalotuzumab, a selective
anti-insulin growth factor 1 receptor monoclonal antibody (IGF1R MoAb), plus erlotinib in a …
anti-insulin growth factor 1 receptor monoclonal antibody (IGF1R MoAb), plus erlotinib in a …
TRIBUTE-A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC)
RS Herbst, D Prager, R Hermann, V Miller… - Journal of Clinical …, 2004 - ascopubs.org
7011 Background: Tarceva™(erlotinib) is a potent reversible HER1/EGFR tyrosine kinase
inhibitor with single-agent antitumor activity. TRIBUTE was a prospective, placebo-controlled …
inhibitor with single-agent antitumor activity. TRIBUTE was a prospective, placebo-controlled …
Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non …
SS Ramalingam, DR Spigel, D Chen… - Journal of clinical …, 2011 - ascopubs.org
Purpose R1507 is a selective, fully human, recombinant monoclonal antibody
(immunoglobulin G1 subclass) against insulin-like growth factor-1 receptor (IGF-1R). The …
(immunoglobulin G1 subclass) against insulin-like growth factor-1 receptor (IGF-1R). The …
MARIPOSA: phase 3 study of first-line amivantamab+ lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer
BC Cho, E Felip, H Hayashi, M Thomas, S Lu… - Future …, 2022 - Taylor & Francis
Third-generation EGFR tyrosine kinase inhibitors (TKIs), such as osimertinib, have
demonstrated efficacy in patients with EGFR-mutant non-small-cell lung cancer; however …
demonstrated efficacy in patients with EGFR-mutant non-small-cell lung cancer; however …
[HTML][HTML] First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advancedEGFR mutation-positive lung adenocarcinoma …
YK Shi, L Wang, BH Han, W Li, P Yu, YP Liu, CM Ding… - Annals of …, 2017 - Elsevier
Background Icotinib has been previously shown to be non-inferior to gefitinib in non-
selected advanced non-small-cell lung cancer patients when given as second-or further-line …
selected advanced non-small-cell lung cancer patients when given as second-or further-line …